A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: NSCLC, Non Small Cell Lung Cancer|RCC, Renal Cell Cancer|Pancreatic Cancer|Urothelial Cancer|Head and Neck Cancer|DLBCL, Diffused Large B Cell Lymphoma|MSS, Microsatellite Stable Colon Cancer|TNBC, Triple Negative Breast Cancer|Melanoma|mCRPC, Metastatic Castration Resistant Prostate Cancer
Interventions: DRUG: NIR178|DRUG: PDR001
Sponsor: Novartis Pharmaceuticals